A coagulation cascade diagram maps the chain of reactions that turns liquid blood into a solid clot. It shows clotting factors, mostly plasma proteins numbered with Roman numerals, activating one another in sequence along three routes: the extrinsic pathway (started by tissue factor at a site of injury), the intrinsic pathway (a chain amplifying the response), and the common pathway, where both meet to produce thrombin and then fibrin. Its main practical use is explaining what clotting tests measure, why particular factor deficiencies cause bleeding, and where anticoagulant drugs act.
This article walks through the diagram step by step, then shows how clinicians apply it. For a broader introduction, see our overview of the coagulation cascade.
Reading the Coagulation Cascade Diagram Step by Step
Most diagrams are drawn as a “Y”: two arms at the top joining into a single stem. Each arrow represents an inactive factor being converted into its active enzyme form, written with a lowercase “a” (for example, factor X becomes Xa). Many steps need calcium and a phospholipid surface, usually provided by activated platelets.
The extrinsic pathway
When a blood vessel is damaged, tissue factor, a protein normally hidden in the vessel wall, is exposed to blood. It binds factor VII, forming the tissue factor–VIIa complex. This complex activates factor X directly, and also activates factor IX. In the body, this is the main trigger of clotting.
The intrinsic pathway
The intrinsic arm runs from factor XII to XI to IX. Activated factor IX joins with its cofactor, factor VIII, to form the “tenase” complex, which activates large amounts of factor X. In living tissue, this arm functions mainly as an amplifier: thrombin generated early on activates factor XI, which feeds more activity into the loop.
The common pathway
Factor Xa combines with its cofactor, factor Va, to form the prothrombinase complex. This converts prothrombin (factor II) into thrombin (factor IIa). Thrombin then cuts fibrinogen (factor I) into fibrin strands, and factor XIIIa cross-links those strands into a stable mesh that holds the platelet plug together.
| Pathway | Key factors | Main role | Lab test that reflects it |
|---|---|---|---|
| Extrinsic | Tissue factor, VII | Starts clotting at the injury site | PT / INR |
| Intrinsic | XII, XI, IX, VIII | Amplifies thrombin production | aPTT |
| Common | X, V, II (prothrombin), I (fibrinogen), XIII | Makes thrombin and a cross-linked fibrin clot | Both PT and aPTT |
The Modern Cell-Based View
The classic Y-shaped diagram was built from test-tube experiments, and it explains lab tests very well. It is less accurate as a picture of what happens in the body. Today, hematologists also use a cell-based model with three overlapping phases:
- Initiation — tissue factor on damaged cells generates a small amount of thrombin.
- Amplification — that thrombin activates platelets and factors V, VIII, and XI.
- Propagation — on the activated platelet surface, tenase and prothrombinase complexes produce a burst of thrombin large enough to form a solid clot.
This model explains an observation the old diagram cannot: people who lack factor XII do not bleed, while people who lack factor VIII or IX (hemophilia) do. It also highlights how central platelet function is to normal clotting.
The Brakes: Natural Anticoagulants and Fibrinolysis
A complete diagram also shows the systems that stop clots from spreading. Antithrombin neutralizes thrombin and factor Xa. Protein C and its cofactor protein S switch off factors Va and VIIIa. Tissue factor pathway inhibitor shuts down the starting complex.
Once healing is under way, plasmin breaks the fibrin clot down, a process called fibrinolysis. The fragments it releases include D-dimer, which is why a D-dimer blood test is used when doctors suspect a clot.
Clinical Applications: Bleeding and Clotting Disorders
The diagram is most useful for locating the fault in a patient’s clotting system. Deficiencies or faulty clotting factor proteins cause bleeding disorders, while overactive clotting or weak brakes cause thrombosis.
- Hemophilia A and B — inherited lack of factor VIII or IX, respectively, causing joint and muscle bleeds.
- Von Willebrand disease — reduced von Willebrand factor, which carries factor VIII and helps platelets stick.
- Vitamin K deficiency and liver disease — reduced production of factors II, VII, IX, and X.
- Factor V Leiden — a variant of factor V that resists being switched off by protein C, raising clot risk.
- Antithrombin, protein C, or protein S deficiency — weakened brakes, leading to venous thrombosis.
- Antiphospholipid syndrome — antibodies that increase clotting risk, even though the lupus anticoagulant paradoxically prolongs clotting times in the lab.
Our article on coagulation disorders covers diagnosis and treatment of each group in more depth.
Using the Diagram to Interpret Coagulation Tests
The prothrombin time (PT) measures the extrinsic and common pathways, and is reported as the INR when monitoring warfarin. The activated partial thromboplastin time (aPTT) measures the intrinsic and common pathways. Reference ranges vary by laboratory, but a typical PT is around 11 to 13.5 seconds and a typical aPTT around 25 to 35 seconds.
| PT | aPTT | Where the problem likely lies | Examples |
|---|---|---|---|
| Prolonged | Normal | Extrinsic pathway (factor VII) | Early warfarin effect, early liver disease, vitamin K deficiency |
| Normal | Prolonged | Intrinsic pathway | Hemophilia A or B, factor XI or XII deficiency, heparin, lupus anticoagulant |
| Prolonged | Prolonged | Common pathway or multiple factors | Advanced liver disease, disseminated intravascular coagulation, low fibrinogen |
A mixing study, in which the patient’s plasma is mixed with normal plasma, helps separate a factor deficiency (the time corrects) from an inhibitor (it does not). Specific factor assays and, in surgery or trauma, viscoelastic tests then fill in the detail. Our guides to coagulation tests for professionals and coagulation tests for patients explain these in more detail.
Where anticoagulants act
The diagram also shows where drugs work. Warfarin lowers the vitamin K-dependent factors II, VII, IX, and X. Heparin boosts antithrombin. Direct oral anticoagulants block a single target: dabigatran inhibits thrombin, while rivaroxaban, apixaban, and edoxaban inhibit factor Xa. You can explore more in our blood clotting guide.
Key Takeaways
- The coagulation cascade diagram shows extrinsic, intrinsic, and common pathways converging on thrombin and fibrin.
- In the body, tissue factor starts clotting and the intrinsic arm amplifies it; the cell-based model describes this more accurately.
- PT reflects the extrinsic and common pathways; aPTT reflects the intrinsic and common pathways.
- Natural anticoagulants and fibrinolysis keep clots in check.
- The diagram pinpoints where factor deficiencies cause bleeding and where anticoagulant drugs act.
Frequently Asked Questions
Why is the extrinsic pathway called “extrinsic”?
Its trigger, tissue factor, comes from outside the blood itself, in the vessel wall and surrounding tissues. The intrinsic pathway was named because all its components are already present within the blood. The names come from early laboratory experiments.
Which clotting factors depend on vitamin K?
Factors II, VII, IX, and X depend on vitamin K, as do the natural anticoagulants protein C and protein S. This is why vitamin K deficiency, liver disease, and warfarin all prolong the PT.
Why doesn’t factor XII deficiency cause bleeding?
In the body, clotting is started by tissue factor rather than factor XII, and thrombin can activate factor XI directly. So although factor XII deficiency prolongs the aPTT in the lab, it does not cause a bleeding tendency.
Is the coagulation cascade diagram still useful?
Yes. It remains the clearest way to interpret PT and aPTT results and to understand where drugs and deficiencies act. Clinicians simply pair it with the cell-based model when thinking about how clots actually form in the body.
